Hyponatremia in the perioperative period: When and how to correct
Michael D. Leise, James Y. Findlay – 26 May 2017
Plasma cystatin C is a predictor of renal dysfunction, acute‐on‐chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis
Daniel Markwardt, Lesca Holdt, Christian Steib, Andreas Benesic, Flemming Bendtsen, Mauro Bernardi, Richard Moreau, Daniel Teupser, Julia Wendon, Frederik Nevens, Jonel Trebicka, Elisabet Garcia, Marco Pavesi, Vicente Arroyo, Alexander L. Gerbes – 25 May 2017 – The development of acute‐on‐chronic liver failure (ACLF) in patients with liver cirrhosis is associated with high mortality rates. Renal failure is the most significant organ dysfunction that occurs in ACLF. So far there are no biomarkers predicting ACLF.
Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis
Agustín Albillos, Javier Zamora, Javier Martínez, David Arroyo, Irfan Ahmad, Joaquin De‐la‐Peña, Juan‐Carlos Garcia‐Pagán, Gin‐Ho Lo, Shiv Sarin, Barjesh Sharma, Juan G. Abraldes, Jaime Bosch, Guadalupe Garcia‐Tsao, on behalf of the Baveno Cooperation – 25 May 2017 – Endoscopic variceal ligation plus beta‐blockers (EVL+BB) is currently recommended for variceal rebleeding prophylaxis, a recommendation that extends to all patients with cirrhosis with previous variceal bleeding irrespective of prognostic stage.
FIB‐4 stage of liver fibrosis predicts incident heart failure among HIV‐infected and uninfected patients
Kaku A. So‐Armah, Joseph K. Lim, Vincent Lo Re, Janet P. Tate, Chung‐Chou H. Chang, Adeel A. Butt, Cynthia L. Gibert, David Rimland, Vincent C. Marconi, Matthew B. Goetz, Maria C. Rodriguez‐Barradas, Matthew J. Budoff, Hilary A. Tindle, Jeffrey H. Samet, Amy C. Justice, Matthew S. Freiberg, for the Veterans Aging Cohort Study Project Team – 24 May 2017 – Liver fibrosis is common, particularly in individuals who are infected with human immunodeficiency virus (HIV). HIV‐infected individuals have excess congestive heart failure (CHF) risk compared with uninfected people.
Unscheduled screening tests cannot be termed as surveillance
Xue‐Jun Xu, Huai‐Zhi Wang, Ping Bie – 24 May 2017
Linking long noncoding RNA to control bile acid signaling and cholestatic liver fibrosis
John Y.L. Chiang – 24 May 2017
Emphasis on harms of hepatocellular carcinoma surveillance: Just pretending innocence after taking advantage?
Zheng Wang, Jun Han, Han Zhang, Meng‐Chao Wu, Tian Yang – 24 May 2017
Reply
Omair Atiq, Jasmin Tiro, Adam C. Yopp, Adam Muffler, Jorge A. Marrero, Neehar D. Parikh, Caitlin Murphy, Katharine McCallister, Amit G. Singal – 24 May 2017
Death and liver transplantation within 2 years of onset of drug‐induced liver injury
- Read more about Death and liver transplantation within 2 years of onset of drug‐induced liver injury
Paul H. Hayashi, Don C. Rockey, Robert J. Fontana, Hans L. Tillmann, Neil Kaplowitz, Huiman X. Barnhart, Jiezhan Gu, Naga P. Chalasani, K. Rajender Reddy, Averell H. Sherker, Jay H. Hoofnagle, for the Drug‐Induced Liver Injury Network (DILIN) Investigators – 23 May 2017 – Drug‐induced liver injury (DILI) is an important cause of death and indication for liver transplantation (fatality). The role of DILI in these fatalities is poorly characterized, particularly when fatalities occur >26 weeks after DILI onset.
Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy
Nancy Reau, Francis Vekeman, Eric Wu, Yanjun Bao, Yuri Sanchez Gonzalez – 23 May 2017 – Despite guideline recommendations, access to hepatitis C virus (HCV) treatment is frequently restricted, with some payers approving therapy for only those with advanced disease or cirrhosis. However, delaying potentially curative treatment until the development of advanced liver disease may have costly consequences in terms of both hepatic complications and extrahepatic manifestations (EHMs) of HCV.